Product logins

Find logins to all Clarivate products below.


Orforglipron

Learn how orforglipron is changing the obesity and T2DM landscape.

What is orforglipron and what sets it apart

Orforglipron could become the first non-peptide oral glucagon-like peptide-1 (GLP-1) receptor agonist (RA) in the obesity/overweight and type 2 diabetes mellitus (T2DM) space.

Novel therapies such as this aim to solve limitations such as suboptimal real-world adherence by improving the administration route via its mechanism of action. It could help shift the treatment paradigm to better align with patients’ needs.

About orforglipron

  • Company: Eli Lilly and Co
  • Type: Small-molecule GLP-1 RA
  • Usage: Once-daily oral administration to manage overweight/obesity and T2DM
    Also being evaluated for obstructive sleep apnea (OSA) and hypertension in individuals with obesity
  • When will orforglipron be available?
    Expected launch 2026: United States (T2DM)
    Expected launch 2027: European Union (obesity and T2DM), Japan (obesity and T2DM), United Kingdom (obesity and T2DM), United States (obesity)

Orforglipron sales and success forecasts

$11.1bn
expected sales for obesity in the G7 markets in 2031*
90%
probability of success for obesity in the United States
$5.2bn
expected sales for T2DM in the G7 markets in 2031*
90%
probability of success for T2DM in the United States

*Because the obesity and T2DM populations overlap, reported sales are not exclusive to each market.

Pills are always easier than injections. Moreover, orforglipron is better as it is not a peptide. Such molecules get absorbed much more easily.

Endocrinologist United States

Drugs in the 2026 list

Related insights

What GLP-1 drugs mean for medtech What GLP-1 drugs mean for medtech
Blog July 2, 2024
What GLP-1 drugs mean for medtech

Are the powerful weight loss and diabetes treatments a lose-lose for medical technology companies? Not necessarily.

The impact of GLP-1RAs on bariatric surgery The impact of GLP-1RAs on bariatric surgery
Webinar
The impact of GLP-1RAs on bariatric surgery

Glucagon-like peptide-1 (GLP-1) receptor agonists have recently witnessed a meteoric rise in popularity for obesity and weight loss. Studies have shown that GLP-1 receptor agonists can be effective for people with obesity, promoting sustained weight management and potentially reducing the risk of weight-related comorbidities. The initial surge in the adoption of these drugs is anticipated...

chevron_left
chevron_right